Neurometrix ( NASDAQ:NURO ) and Quantrx Biomedical ( OTCMKTS:QTXB ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
Institutional & Insider Ownership
13.5% of Neurometrix shares are owned by institutional investors. 6.4% of Neurometrix shares are owned by insiders. Comparatively, 21.9% of Quantrx Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Neurometrix and Quantrx Biomedical’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Neurometrix 0.14% 0.31% 0.19% Quantrx Biomedical N/A -88.56% -70.37% Earnings and Valuation
This table compares Neurometrix and Quantrx Biomedical’s gross revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neurometrix $16.09 million 0.40 $20,000.00 N/A N/A Quantrx Biomedical N/A N/A -$740,000.00 N/A N/A Neurometrix has higher revenue and earnings than Quantrx Biomedical.
Volatility & Risk
Neurometrix has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Quantrx Biomedical has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.
This is a summary of current recommendations for Neurometrix and Quantrx Biomedical, as reported by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurometrix 0 0 1 0 3.00 Quantrx Biomedical 0 0 0 0 N/A Summary
Neurometrix beats Quantrx Biomedical on 8 of the 10 factors compared between the two stocks.
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.
About Quantrx Biomedical Quantrx Biomedical logo QuantRx Biomedical Corporation engages in the development and commercialization patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company’s PAD products are used for the treatment of hemorrhoids, minor vaginal infections, urinary incontinences, general catamenial uses, and other medical needs. It also provides InSync, a feminine hygienic interlabial padand; Unique miniform, which is available as a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad, for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. The company was incorporated in 1986 and is based in Tualatin, Oregon.
Receive News & Ratings for Neurometrix Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Neurometrix and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Neurometrix (NURO) & Quantrx Biomedical (QTXB) Head to Head Review